Trials That Matter: The Effect of a Fixed-Dose Combination of an Angiotensin-Converting Enzyme Inhibitor and a Diuretic on the Complications of Type 2 Diabetes

Editorials4 March 2008Trials That Matter: The Effect of a Fixed-Dose Combination of an Angiotensin-Converting Enzyme Inhibitor and a Diuretic on the Complications of Type 2 DiabetesGeorge L. Bakris, MD and Michael Berkwits, MD, MSCE, Deputy EditorGeorge L. Bakris, MDFrom the University of Chicago, Chicago IL 60637, and the American College of Physicians, Philadelphia, PA 19106.Search for more papers by this author and Michael Berkwits, MD, MSCE, Deputy EditorFrom the University of Chicago, Chicago IL 60637, and the American College of Physicians, Philadelphia, PA 19106.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-148-5-200803040-00012 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Providers who care for patients with type 2 diabetes often focus on lowering levels of glucose and hemoglobin A1c. Strict control of these glycemic measures reduces the incidence of microvascular complications of the disease, such as retinopathy and nephropathy, but has little effect on macrovascular complications, such as myocardial infarction and stroke, from which most patients with type 2 diabetes ultimately die. Prevention of these macrovascular complications requires equal attention to lowering blood pressure and lipid levels. Diabetes care would be simplified enormously if physicians had a treatment that could safely reduce both kinds of complications.The ADVANCE (Action in ...References1. Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, et al; ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370:829-40. [PMID: 17765963] CrossrefMedlineGoogle Scholar2. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317:703-13. [PMID: 9732337] CrossrefMedlineGoogle Scholar3. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755-62. [PMID: 9635947] CrossrefMedlineGoogle Scholar4. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-97. [PMID: 12479763] MedlineGoogle Scholar5. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al; INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized, controlled trial. JAMA. 2003;290:2805-16. [PMID: 14657064] CrossrefMedlineGoogle Scholar6. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022-31. [PMID: 15207952] CrossrefMedlineGoogle Scholar7. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000;356:366-72. [PMID: 10972368] CrossrefMedlineGoogle Scholar8. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;326:1419. [PMID: 12829553] CrossrefMedlineGoogle Scholar9. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000;355:253-9. [PMID: 10675071] CrossrefMedlineGoogle Scholar10. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6, 105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033-41. [PMID: 11589932] CrossrefMedlineGoogle Scholar11. Bakris G, Molitch M, Hewkin A, Kipnes M, Sarafidis P, Fakouhi K, et al; STAR Investigators. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care. 2006;29:2592-7. [PMID: 17130190] CrossrefMedlineGoogle Scholar12. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-13. [PMID: 12493255] CrossrefMedlineGoogle Scholar13. Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N, et al; Trial of Preventing Hypertension (TROPHY) Study Investigators. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med. 2006;354:1685-97. [PMID: 16537662] CrossrefMedlineGoogle Scholar14. Cushman WC, Grimm RH, Cutler JA, Evans GW, Capes S, Corson MA, et al; ACCORD Study Group. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol. 2007;99:44i-55i. [PMID: 17599425] CrossrefMedlineGoogle Scholar15. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-72. [PMID: 12748199] CrossrefMedlineGoogle Scholar16. National Kidney Foundation, Kidney Disease Outcome Quality Initiative. Guideline 3: Management of Hypertension in Diabetes and Chronic Kidney Disease. In: KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. New York: National Kidney Foundation; 2007. Accessed at www.kidney.org/professionals/kdoqi/guideline_diabetes/guide3.htm on 25 January 2008. Google Scholar17. Executive summary: standards of medical care in diabetes—2008. Diabetes Care. 2008;31:S5-11. CrossrefGoogle Scholar18. Gerbino PP, Shoheiber O. Adherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agents. Am J Health Syst Pharm. 2007;64:1279-83. [PMID: 17563050] CrossrefMedlineGoogle Scholar19. Petrilla AA, Benner JS, Battleman DS, Tierce JC, Hazard EH. Evidence-based interventions to improve patient compliance with antihypertensive and lipid-lowering medications. Int J Clin Pract. 2005;59:1441-51. [PMID: 16351677] CrossrefMedlineGoogle Scholar20. Jamerson K, Bakris GL, Dahlöf B, Pitt B, Velazquez E, Gupte J, et al; ACCOMPLISH Investigators. Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Press. 2007;16:80-6. [PMID: 17612905] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From the University of Chicago, Chicago IL 60637, and the American College of Physicians, Philadelphia, PA 19106.Disclosures:Consultancies: G.L. Bakris (Merck, Boehringer-Ingelheim, GlaxoSmithKline, Novartis, Abbott Laboratories, Forest Pharmaceuticals).Grants received: G.L. Bakris (National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases, GlaxoSmithKline, Forest Pharmaceuticals).Grants pending: G.L. Bakris (National Institutes of Health Alternative Medicine Institute). Royalties: G.L. Bakris (Dr. Bakris is the editor of many textbooks on hypertension).Corresponding Author: Michael Berkwits, MD, MSCE, American College of Physicians, 190 N. Independence Mall West, Philadelphia, PA 19106.Current Author Addresses: Dr. Bakris: University of Chicago, 924 East 57th Street, Suite 104, Chicago, IL 60637.Dr. Berkwits: American College of Physicians, 190 N. Independence Mall West, Philadelphia, PA 19106. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByPathogenesis and Treatment of Microalbuminuria in Patients With Diabetes: The Road AheadADVANCE: Blood Pressure Lowering in Diabetes 4 March 2008Volume 148, Issue 5Page: 400-401KeywordsACE inhibitorsBlood pressureDiureticsDrugsHypertensionMyocardial infarctionRetinopathySystolic pressureType 2 diabetesVascular diseases ePublished: 4 March 2008 Issue Published: 4 March 2008 CopyrightCopyright © 2008 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...